<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

OrganoidXplore™: Routine and Rapid Compound Testing in a Large Panel of Organoids

OrganoidXplore™: Routine and Rapid Compound Testing in a Large Panel of Organoids
4:30

OrganoidXplore™, developed by Crown Bioscience, is a large-scale organoid panel screen, executed every three months, in which clients can include their compounds for testing on organoid viability. It comprises a genetically characterized heterogeneous panel of tumor organoids and matching organoids derived from healthy epithelium from the same patients.

OrganoidXplore delivers biologically and clinically relevant data to support drug discovery decision making, including patient stratification and drug repurposing, biomarker development, and mechanism of action studies. An innovative aspect of the OrganoidXplore platform is its use of assay-ready organoid technology, which enables the screening of large panels and delivery of results with timelines equivalent to conventional 2D screens. This unique platform provides comprehensive insight into compound performance, developed to deliver results economically with remarkably short timelines.

Model selection diversity

The OrganoidXplore platform comprises 50 well-characterized organoid models covering seven cancer types: breast, cervical, colorectal, lung, melanoma, ovarian, and pancreatic. The genetic backgrounds and mutations represent diverse mechanisms of action and tumor types that are relevant for contemporary drug discovery. “Researchers can elect to screen compounds in the full panel, or in subsets based on mutation, indication or specific biomarker,” explains Hester Bange, Associate Director and Head of OrganoidXplore. “There is also the option for ultra-flexible panel design (20+ model selection) to meet specific research requirements. Moreover, because the organoids in the OrganoidXplore panel are derived from Crown Bioscience’s patient-derived xenograft models (PDXOs), there is the potential for direct in vivo translation in matching PDX models.”

Routine quarterly panel run and fast turn-around times

OrganoidXplore is based on Crown Bioscience’s unique assay-ready technology and biobank establishment. Hubrecht organoid technology (HUB) protocols, for which Crown has an exclusive license for oncology services, ensure that the genetic and epigenetic makeup of the original tissue, including clinically relevant mutations, is preserved. The use of biobanked cryopreserved organoids enables the uncoupling of organoid expansion, which is asynchronous and can take months, from the relatively quick compound testing phase. This dramatically reduces overall assay timelines compared with the traditional methodology that uses freshly prepared organoids, as illustrated by recent posters presented at the AACR annual meeting and ANE international conference 2023. “Our data show that using assay-ready organoids for drug sensitivity testing shortens turnaround times to just six weeks from study initiation without compromising data quality,” reports Bange. “In addition, the significantly reduced logistical burden associated with using assay-ready organoids frees up researchers’ time to be spent on other tasks.”

Robust performance

Rigorous testing of cell viability in response to a range of standard-of-care oncology drugs shows high correlation between freshly prepared organoids and assay-ready organoids, demonstrating that the assay-ready cryopreservation methodology does not impair organoid biology or assay quality. Furthermore, the OrganoidXplore platform demonstrates consistent assay performance, with high Z-factors and low intra-and inter-plate variability indicating excellent experimental reproducibility between independent OrganoidXplore runs.

Fast-track your oncology project with OrganoidXplore

OrganoidXplore is a unique solution for oncology drug discovery that makes large-scale organoid panel screening accessible and economically viable for testing—even one single compound—with delivery of results in a matter of weeks.  Learn more about OrganoidXplore.

Looking for other models not in the OrganoidXplore panel, or other readouts, such as those requiring high content imaging, genomics or proteomics? The technology can be applied to Crown’s full collection of over 600 organoids, for a truly custom panel, and using a broad range of endpoints. Learn more about Crown’s broader range of organoid services.